(2s)-1-[[(叔丁氧基)羰基]氮杂环庚烷-2-羧酸 | 155905-76-3

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (2s)-1-[[(叔丁氧基)羰基]氮杂环庚烷-2-羧酸
• 英文名称: (2S)-1-(tert-butoxycarbonyl)-2-azepanecarboxylic acid
• 英文别名: (S)-1-(tert-butoxycarbonyl) azepane-2-carboxylic acid；(S)-1-(tert-butoxycarbonyl)-azepane-2-carboxylic acid；(S)-1-(terf-butoxycarbonyl)azepane-2-carboxylic acid；(S)-1-(tert-butoxycarbonyl)azepane-2-carboxylic acid；(S)-azepane-1,2-dicarboxylic acid 1-tert-butyl ester；(S)-perhydro-azepine-1,2-dicarboxylic acid 1-tert-butyl ester；(S)-1-(Boc)azepane-2-carboxylic acid；(2S)-1-[(2-methylpropan-2-yl)oxycarbonyl]azepane-2-carboxylic acid
• CAS: 155905-76-3
• 化学式: C₁₂H₂₁NO₄
• 分子量: 243.303
• InChiKey: BKMVFOKQLCHCPK-VIFPVBQESA-N

物化性质

• 熔点：
  110-112 °C
• 沸点：
  369.0±35.0 °C(Predicted)
• 密度：
  1.133±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  66.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2s)-1-[[(叔丁氧基)羰基]氮杂环庚烷-2-羧酸 在 palladium on activated charcoal 4-二甲氨基吡啶 、 2-氯-1-甲基吡啶碘化物 、 氢气 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 达卡巴嗪 、 三乙胺 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 25.0 ℃ 、344.74 kPa 条件下， 反应 41.5h， 生成 (7R,10S,13R,16S,19R,22S,25R,27aS)-7,19-Dibenzyl-10,16,22-triisobutyl-11,13,17,23,25-pentamethyl-dodecahydro-8,14,20,26-tetraoxa-5a,11,17,23-tetraaza-cycloheptacyclotetracosen-6,9,12,15,18,21,24,27-octaone
  参考文献：
  名称：

  Restricted Conformation Analogues of an Anthelmintic Cyclodepsipeptide

  摘要：

  Six analogues of the anthelmintic cyclodepsipeptide PF1022A were prepared, each containing a small ring fused to the macrocycle to restrict the number of conformations the larger ring can adopt. It was anticipated that such conformational changes could lead to enhanced biological activity and selectivity. The analogues form two series of three members each. In one series, a carbon-based molecular bridge joins the methyl of a leucine residue with the methyl of its closest lactic acid residue to form five-, six-, and seven-membered lactam rings. In the second series, a leucine residue is replaced with five-, six-, and seven-membered nitrogen heterocycles. Decreasing the size of the small ring in the lactam. series increasingly distorts the macrocycle and consistently decreases activity relative to PF1022A. In the leucine series, a similar trend is observed. Molecular modeling of PF1022A along with the analogues described herein suggests that the ability to exist in a highly symmetrical conformational state is a necessary condition for biological activity.

  DOI：

  10.1021/jm020482k
• 作为产物：
  描述：

  氮杂环庚烷-2-甲酸 在 (R)-1-(1-萘基)乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 乙醚 、 水 为溶剂， 反应 1.0h， 生成 (2s)-1-[[(叔丁氧基)羰基]氮杂环庚烷-2-羧酸
  参考文献：
  名称：

  一种多元氮杂环状非天然手性氨基酸及其合 成方法

  摘要：

  本发明涉及一种多元氮杂环状非天然手性氨基酸及其合成方法，其可以应用于合成抗生素等药物的分子砌块。通过运用2‑氨基丙二酸二乙酯与卤代烷烃的取代、成环、脱羧反应，再通过拆分可制得多元氮杂环状非天然手性氨基酸。本发明所述的合成新方法路线简洁、成本低、操作方便、易于进行商业化生产，所得产品手性纯度高，有很好的应用前景。

  公开号：

  CN108752253B

文献信息

• [EN] ALKYNE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS<br/>[FR] COMPOSÉS ALCYNE POUR LE TRAITEMENT DE TROUBLES IMMUNITAIRES ET INFLAMMATOIRES
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2017035415A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I'" or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.

  提供含有公式I、I"和I'"的补体因子D抑制剂、使用方法和制备过程，或其药物可接受的盐或组合物。本文所述的抑制剂针对因子D并抑制或调节补体级联反应。本文所述的因子D抑制剂减少了补体的过度激活。
• [EN] ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS<br/>[FR] COMPOSÉS ARYLE, HÉTÉROARYLE, ET HÉTÉROCYCLIQUES POUR LE TRAITEMENT DE TROUBLES IMMUNITAIRES ET INFLAMMATOIRES
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2017035409A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I'" or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

  提供含有公式I、I"和I'"的补体因子D抑制剂、使用方法和制备过程，或其药物可接受的盐或组合物。本文所述的抑制剂针对因子D并抑制或调节补体级联反应。本文所述的因子D抑制剂减少了补体的过度激活。
• [EN] ARYL, HETEROARY, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS PHARMACEUTIQUES ARYLE, HÉTÉROARYLES ET HÉTÉROCYCLIQUES POUR LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2018160889A1

  公开（公告）日：2018-09-07

  Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

  提供了抑制补体因子D的抑制剂、药物组合物及其用途，以及它们的制备方法。所提供的化合物包括公式I、公式II、公式III、公式IV和公式V，或其药学上可接受的盐、前药、同位素类似物、N-氧化物或其分离异构体，可选地在药学上可接受的组合物中。本文描述的抑制剂针对因子D并抑制或调节补体级联反应。
• [EN] PHOSPHONATE COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS<br/>[FR] COMPOSÉS DE PHOSPHONATE POUR LE TRAITEMENT DE TROUBLES IMMUNITAIRES ET INFLAMMATOIRES
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2017035417A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I''' or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduce the excessive activation of complement.

  提供含有公式I、I"和I'''或其药物可接受的盐或组合物的补体因子D抑制剂的化合物、使用方法和制备过程。本文所述的抑制剂针对因子D并抑制或调节补体级联。本文所述的因子D抑制剂减少了补体的过度激活。
• [EN] ETHER COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS<br/>[FR] COMPOSÉS D'ÉTHER POUR LE TRAITEMENT DE TROUBLES IMMUNITAIRES ET INFLAMMATOIRES
  申请人：ACHILLION PHARMACEUTICALS INC

  公开号：WO2017035411A1

  公开（公告）日：2017-03-02

  Compounds, methods of use, and processes for making inhibitors of complement Factor D are provided comprising Formula I, I" and I‴ or a pharmaceutically acceptable salt or composition thereof. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade. The inhibitors of Factor D described herein reduces the excessive activation of complement.

  提供包含公式I、I"和I‴的补体因子D抑制剂、使用方法和制备过程，或者包含药用可接受盐或其组合物。本文所述的抑制剂针对因子D并抑制或调节补体级联反应。本文所述的因子D抑制剂减少了补体的过度激活。